Kovač, MD, PhD V, Zwitter M, Stanic K, Rajer M, Kern I, Vrankar M, et al. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations. Radiol Oncol [Internet]. 2014 Oct. 26 [cited 2026 Jun. 10];48(4). Available from: https://radioloncol.com/index.php/ro/article/view/2233